Authors
Latest:
Dr. Mittendorf on QoL With Neoadjuvant Atezolizumab/Chemo in Early TNBCElizabeth A. Mittendorf, MD, PhD, discusses patient-reported quality of life associated with neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer.
Latest:
Listen Up: Speech Recognition Technology Spreads in EHR EraMedical records have changed significantly in the past decade, with powerful servers and digital archives replacing rooms jammed with filing cabinets and folders stuffed with hand-scribbled notes.
Latest:
Elizabeth Blasiak Discusses the ONS CongressElizabeth Blasiak on the Significance of the ONS Congress
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Older Breast Cancer Patients Require Special ConsiderationTreating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.
Latest:
Dr. Garner Discusses the myRisk Hereditary Cancer TestElizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.
Latest:
Dr. Elizabeth H. Baldini on Systemic Therapy for SarcomaElizabeth H. Baldini, MD, MPH, director, radiation oncology, center for sarcoma and bone oncology, associate professor of radiation oncology, Harvard Medical School, discusses sarcoma
Latest:
Dr. Shpall on Therapeutic Agents for the Treatment of CLLElizabeth J. Shpall, MD, professor, deputy department chair, Department of Stem Cell Transplantation, Division of Cancer Medicine, medical director, Cell Therapy Laboratory, director, Cord Blood Bank, the University of Texas MD Anderson Cancer Center, discusses idelalisib and ibrutinib for the treatment of patients with chronic lymphocytic leukemia.
Latest:
Expert Discusses Value of Venetoclax After BCR Inhibition in CLLJeffrey Jones, MD, discusses promising early data for venetoclax in chronic lymphocytic leukemia after progression on BCR-pathway inhibitors, as well as the next steps with the research.
Latest:
Dr. Gore on Toxicity in Elderly Lung Cancer PatientsDr. Elizabeth Gore, from the Medical College of Wisconsin, on Toxicity in Elderly Lung Cancer Patients
Latest:
Dr. Swisher on the Limitations of HRD as a Biomarker in Ovarian CancerElizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.
Latest:
Dr. Mittendorf on Vaccines as Prevention for Breast CancerElizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the possibility of using vaccines as a preventative measure for breast cancer, particularly to fight recurrence.
Latest:
Dr. Mittendorf Discusses Rationale for Updating the AJCC Staging SystemElizabeth Mittendorf, MD, PhD, discusses the rationale for updating the AJCC staging system in patients with breast cancer. This system was originally developed in the 1970s but is still used today.
Latest:
Dr. Henske on the Potential Role of Glutathione in Chromophobe RCCElizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.
Latest:
Key Takeaways in the Treatment of Advanced RCC From KCRS 2023Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.
Latest:
Key Takeaways on Updates in Bladder CancerElizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.
Latest:
Renal Cell Carcinoma: Future Evolutions in CareShared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.
Latest:
Dr. Swisher on the Phase III VELIA Results in Ovarian CancerElizabeth M. Swisher, MD, discusses results from the phase III VELIA/GOG-3005 trial in ovarian cancer.
Latest:
Long-term Aspirin Use Decreases Risk of GI Cancers, Especially ColorectalA recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Latest:
Ellen T. Matloff on Changes to the Field of Genetic TestingEllen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.
Latest:
Navigating COVID-19 Challenges to Provide Optimal Cancer CareGilberto De Lima Lopes, MD, discusses the impact of COVID-19 on his practice and how he is coping with the changes caused by the pandemic.
Latest:
Ellyn Matthews Addresses Misconceptions About Sleep DisturbancesEllyn Matthews, PhD, RN, AOCNS, CBSM, who holds the Elizabeth Stanley Cooper Endowed Chair in Oncology Nursing at the University of Arkansas for Medical Sciences, addresses common misconceptions that patients with cancer have about sleep disturbances.
Latest:
Dr. Kandil on Minimally Invasive Surgical TechniquesEmad Kandil, MD, Chief of Endocrine Surgery at the Tulane University School of Medicine, discusses advances in surgical procedures.
Latest:
Robotic Surgery Represents a Notable Advance in Thyroid Cancer CareAmid a rising incidence of thyroid cancer, endocrine surgeons have increasingly explored minimally invasive approaches for operating on patients with the disease.
Latest:
Chip Petricoin on the Discovery of New BiomarkersEmanuel F. "Chip" Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the discovery of new biomarkers in breast cancer.
